InvestorsHub Logo
Followers 804
Posts 27284
Boards Moderated 0
Alias Born 09/11/2013

Re: LIVED post# 303037

Friday, 06/19/2020 7:36:46 AM

Friday, June 19, 2020 7:36:46 AM

Post# of 403568
Awesome find ZROYPU, thank you for sharing the info.

Included in the article:


Nano cap Innovation Pharmaceuticals (OTCQB:IPIX +28.3%) announces new results from ongoing laboratory tests evaluating Brilacidin’s effects on the SARS-CoV-2 virus in cell cultures.

In a human lung epithelial cell line, Brilacidin reduced viral load by 95% and 97%, respectively, compared to control, at two therapeutic concentrations tested while being non-toxic to the cells.

The company says the new data reinforce previous testing, in VERO cells, where Brilacidin showed inhibition of 75% against SARS-CoV-2 compared to control.

Results, when completed, will be submitted for publication. Data generated to date supported a federal grant application filed last week by RBL, the testing laboratory, in collaboration with IPIX seeking funds to finance studies evaluating Brilacidin as a pan-coronavirus therapeutic.



https://nai500.com/blog/2020/06/healthcare-roundup-fda-yanks-emergency-use-authorization-of-chembio-covid-19-blood-test-gilead-readies-pediatric-study-of-remdesivir/

$IPIX

Imho
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News